PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces SensoLyte® Deubiquitination Assay Kit - AnaSpec, EGT Group, is pleased to introduce the SensoLyte® 440 Deubiquitination Assay Kit. This kit provides a convenient assay for inhibitors/activators screening in deubiquitinylation or for continuous assay of enzyme activity
AnaSpec Introduces SensoLyte® Deubiquitination Assay Kit

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2011/10/11 - AnaSpec, EGT Group, is pleased to introduce the SensoLyte® 440 Deubiquitination Assay Kit. This kit provides a convenient assay for inhibitors/activators screening in deubiquitinylation or for continuous assay of enzyme activity.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A natural substrate, ubiquitin, coupled with the AMC (7-amino-4-methylcoumarin) fluorophore is used in the kit. Upon cleavage by a deubiquitin protease, this substrate generates a blue fluorophore that can be detected at excitation/emission=354/442 nm. The substrate supplied in the kit is exquisitely sensitive for ubiquitin hydrolases (UCHs). The detection limit can reach as low as 3.7 pg/mL.

Modification of proteins with ubiquitin is a key step in protein degradation controlling many intracellular processes such as transcription, cell cycle progression, receptor internalization, and DNA repair.1 Recent studies have demonstrated that regulation also occurs at the level of deubiquitination.2,3 Deubiquitinating enzymes (DUBs) are proteases that reverse ubiquitin modifications.

Over 100 DUBs have been identified in humans. They are grouped into five distinct families based on their sequence similarities and mechanisms of action. Four of the families are cysteine proteases, while the fifth is a novel type of zinc-dependent metalloprotease.4,5 The majority of human DUBs belong to two cysteine proteases families, the ubiquitin specific proteases (USPs) and the ubiquitin carboxyterminal hydrolases (UCHs). Both protease families hydrolyze the peptide bond downstream of the C terminus of ubiquitin, which is either a classic peptide bond in the proforms of ubiquitin or an isopeptide bond to an e-amino group of a lysine residue within an ubiquitin modified protein. DUBs have been implicated in the pathogenesis of many human diseases, such as neurodegenerative disorders and cancer.6,7 Consequently they have become actively studied molecular targets for drug discovery.8,9

AnaSpec, EGT Group, is also pleased to introduce the SensoLyte® 520 Deubiquitination Assay Kit. This kit, which employs a peptide substrate conjugated to a green fluorophore, is also good for inhibitors/activators screening in deubiquitinylation or for continuous assay of enzyme activity. Bright green fluorescence is generated upon protease cleavage and can be detected at excitation/emission=490/520 nm. The long wavelength spectra of the green fluorophore released provides less interference from other reaction components.

References
1. Hershko, A. and Ciechanover, A. Annu Rev Biochem 67, 425 (1998).
2. Amerik, AY. and M. Hochstrasser, Biochim Biophys Acta 1695, 189 (2004)
3. Kim, J.H. et al. J Biochem. 134, 9 (2003).
4. Soboleva, T.A. Curr Protein Pepy Sci 5, 191 (2004).
5. Karen, H. et al. Biochem J 414, 161 (2008).
6. Setsuie, R. et al. Neurochem Int. 51, 105 (2007).
7. Hussain, S. et al. Cell Cycle 8, 1688 (2009).
8. Nicholson, B. et al. Future Onco l3, 191 (2007).
9. Colland, F. Biochem Soc Trans 38, 137 (2010).

AnaSpec, EGT Group

AnaSpec (anaspec.com), EGT Group is a leading provider of integrated proteomics and genomics solutions™ for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces SensoLyte® Deubiquitination Assay Kit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)